David Miklos

Clinical Trials

• A Phase II Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft versus Host Disease Recruiting
• Bone Marrow Grafting for Leukemia and Lymphoma Recruiting
• NMDP Research Database for Allogeneic Unrelated Hematopoietic Stem Cell Transplantation Recruiting
• Allogeneic HCT using Nonmyeloablative Host Conditioning with TLI & ATG vs SOC in AML Recruiting
• Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma Recruiting
• Chronic GVHD Cohort Protocol Recruiting
• Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Recruiting
• Defibrotide for Hematopoietic SCT Patients With Severe Hepatic VOD: a Treatment IND Study Recruiting
• Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease Recruiting
• Imatinib Mesylate and Nilotinib After Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia Recruiting
• Ph II of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG Recruiting
• Ph II of Non-myeloablative Allgnc Trnsplnt Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma Recruiting
• Phase I/II of a CpG-Activated Whole Cell Vaccine Followed by Autologous “Immunotransplant” for MCL Recruiting
• Phase II Poor Risk Diffuse Large B-cell Lymphoma (DLBCL) of Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) Followed by Matched Allogeneic Hematopoietic Transplantation as Consolidation to Autologous Hematopoietic Cell Transplantation (AHCT) Recruiting
• Research Sample Repository for Allogeneic Unrelated Hematopoietic Stem Cell Transplantation Recruiting
• Sirolimus & Mycophenolate Mofetil as GVHD prophylaxis in Myeloablative, Matched Related Donor HCT Recruiting
• Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease Recruiting
• Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) Recruiting
• A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Palifermin (rHuKGF) in the Reduction of Acute Graft Versus Host Disease in Subjects With Hematologic Malignancies Undergoing Allogeneic Marrow/PBPC Transplantation Completed
• Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients No longer recruiting
• High -Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma No longer recruiting
• High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma No longer recruiting
• Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors For The Treatment Of Multiple Myeloma Completed
• Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies No longer recruiting
• Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells Completed